An observational study in Infertility Female, sponsored by Centre Hospitalier Universitaire de la Guadeloupe. Recruiting at 1 site in Guadeloupe. Open to female participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2025-11-17.
Sponsored by Centre Hospitalier Universitaire de la Guadeloupe · Observational
Chlordecone is an organochlorine pesticide used in the French West Indies (FWI) from 1972 to 1993 to control the banana root borer. Due to its very long persistence the population continues to be exposed to this chemical through their food consumptions. Although, chlordecone have been associated in animal study impairment of ovarian reserve, to date, no study has been published concerning the link between chlordecone exposure and female fertility. The main objective of this project is to study the association between chlordecone exposure and anti-mullerian hormone (AMH) in women consulting for couple infertility in Guadeloupe.
Chlordecone is an organochlorine pesticide used in the French West Indies (FWI) from 1972 to 1993 to control the banana root borer. Due to its very long persistence the population continues to be exposed to this chemical through their food consumptions. Chlordecone is an endocrine-disrupting chemical with well-defined estrogenic and progestagenic properties in vivo and in vitro. To date, no study has been published concerning the link between chlordecone exposure and female fertility. Nevertheless, mammalian studies in females have consistently reported that chlordecone exposure impairs ovulation and leads to a reduced ovarian reserve. In addition, there are questions about the impact of other environmental exposures, including by non-targeted approaches, and also of the vaginal and endometrial microbiome on female fertility.
552 studies on the registry are indexed under Infertility, Female; 137 are open to participants now.
This study's planned enrollment of 634 is above the median of 161 across 162 observational studies indexed under Infertility, Female.
Browse Infertility, Female studies →Centre Hospitalier Universitaire de la Guadeloupe is the lead sponsor of 50 studies on the registry; 25 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Women consulting for couple infertility in Guadeloupe.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Levels of AMH according to terciles of chlordecone levels.
The purpose is to study the association between chlordecone exposure and AMH levels in women consulting for couple infertility in Guadeloupe.
Time frame: AMH levels will be measured during the assessment conducted for assisted reproductive technology (ART) and will date from less than one year before inclusion
Number of antral follicles according to terciles of chlordecone levels.
Transvaginal ultrasound for antral follicle count will be performed between days 2 and 4 of the spontaneous menstrual cycle, the number of antral follicles corresponds to the total number of antral follicles in both ovaries, with a diameter between 2 and 10 mm.
Time frame: between days 2 and 4 of the spontaneous menstrual cycle
AMH levels and antral follicle count according to the levels of other POPs
AMH levels and antral follicle count
Time frame: baseline
relationship between exposure to chlordecone and other POPs and the risk of the main causes of female infertility
main causes of female infertility : Endometriosis ; Polycystic ovary syndrome (PCOS) ; Decreased ovarian reserve
Time frame: baseline
Chlordecone levels according to the outcomes of IVF/ICSI management:
relationship between occupational exposure to solvents and others factors described : * Endometrial thickness, * Peak estraiol, * Number of oocytes collected, * Number of mature oocytes collected, * Number of zygotes, * Embryo quality, * Blastocyst number, * Number of frozen embryos, * Biological pregnancy, * Clinical pregnancy, * Live birth.
Time frame: changes from baseline to 2 years after
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de la Guadeloupe